DO YOU PAY TAXES ON YOUR SOCIAL SECURITY BENEFITS?

Thu, 11 Mar 2010 12:43:44 GMT

A LETTER TO A MINNESOTA LEGISLATOR

Tue, 09 Mar 2010 06:31:43 GMT

PROMISING ALZHEIMER’S DRUG FAILS CRUCIAL TEST, DIMS HOPES FOR CURE

Thu, 04 Mar 2010 00:00:00 GMT

Dimebon, an Alzheimer’s drug developed by drug king Pfizer Inc. and its partner Medivation Inc., failed to improve thinking and daily functioning for patients with mild to moderate Alzheimer’s disease in a six-month test, stunning proponents of the drug.

Dimebon had prevented these symptoms from worsening in a previous test. Other studies are continuing with the hope that Dimebon, when combined with other Alzheimer’s drugs or used for longer treatment periods, could be effective.

Doctor Donald Petersen, who chairs the Alzheimer’s Association medical and scientific advisory council, pointed out that Dimebon was the drug “nearest to approval,” and that it could have been on the market in a little as two years. “It’s a setback,” Petersen concluded, noting that other Alzheimer’s-fighting drugs are much earlier in the approval process.

According to the Alzheimer’s Association, more than five million Americans have Alzheimer's disease, a number that’s forecast to grow to 16 million by 2050.

Great Places Blog

DO YOU PAY TAXES ON YOUR SOCIAL SECURITY BENEFITS?

A LETTER TO A MINNESOTA LEGISLATOR

PROMISING ALZHEIMER’S DRUG FAILS CRUCIAL TEST, DIMS HOPES FOR CURE